Physician profile
Won Seok Jo
NPI 1245215144
$7,031.85
in general payments reported to CMS, 2019-2025
25 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $517 · 2021: $986 · 2022: $1,230 · 2023: $1,252 · 2024: $1,246 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.32 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.46 | 2019-2025 | |
| Gilead Sciences, INC. | $1,027.63 | 2019-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $983.44 | 2019-2024 | Xifaxan, Trulance |
| Celgene Corporation | $633.28 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $624.16 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $412.06 | 2019-2025 | |
| Ardelyx, INC. | $397.59 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $316.30 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $228.09 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $214.16 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Madrigal Pharmaceuticals | $192.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $184.69 | 2019 | |
| Pentax of America, INC. | $132.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.54 | 2023-2025 | Dupixent |
| Genzyme Corporation | $111.34 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $59.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.22 | 2023 | Entyvio |
| Ironwood Pharmaceuticals, INC | $42.78 | 2019-2020 | |
| Boston Scientific Corporation | $42.64 | 2022 | |
| Ferring Pharmaceuticals INC. | $41.25 | 2021-2024 | Clenpiq |
| Alnylam Pharmaceuticals INC. | $37.78 | 2021-2025 | Givlaari |
| Lilly USA, LLC | $34.05 | 2024 | Omvoh |
| Allergan, INC. | $18.67 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.10 | 2023 | Terlivaz |
| Albireo Pharma, INC. | $14.67 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Seok Jo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.